In a patient with a urinary tract infection caused by Proteus mirabilis (>100,000 CFU/mL) that is susceptible to ceftriaxone and resistant to ciprofloxacin, currently receiving ceftriaxone 1 g IV daily, with improving urinalysis but persistent leukocyte esterase and nitrite positivity, normal renal function (creatinine 0.59 mg/dL, eGFR 104 mL/min), and no repeat urine culture yet, should the ceftriaxone regimen be continued or altered?

Continue Ceftriaxone 1g IV Daily and Obtain Repeat Urine Culture Immediately

I recommend continuing ceftriaxone 1g IV daily for now, but you must obtain a repeat urine culture immediately to guide further management. The persistent urinalysis abnormalities after several days of appropriate therapy for a susceptible organism warrant investigation for treatment failure, inadequate dosing, or a complicating factor.

Clinical Reasoning

Why Continue Ceftriaxone Currently

Your patient has documented Proteus mirabilis susceptible to ceftriaxone, making this an appropriate targeted therapy 1. The organism is resistant to ciprofloxacin, so switching to a fluoroquinolone would be inappropriate. While the IDSA guidelines note that β-lactams are "less effective than other available agents for treatment of pyelonephritis" 1, ceftriaxone remains acceptable when the organism is susceptible and other agents cannot be used.

The Dosing Problem

However, ceftriaxone 1g daily is likely underdosed for this infection. The 2024 EAU guidelines recommend ceftriaxone 1-2g daily, with the notation that "lower dose studied, but higher dose recommended" 2. For a complicated UTI with Proteus mirabilis (which produces urease and can form struvite stones, making infections more difficult to eradicate), I would strongly consider increasing to ceftriaxone 2g IV daily.

Duration Concerns

The IDSA guidelines recommend 10-14 days total duration for β-lactam therapy in pyelonephritis 1. You haven't specified how many days the patient has received treatment, but if he's only been on therapy for a few days, the persistent UA abnormalities may simply reflect incomplete treatment response rather than failure.

The Persistent Urinalysis Findings

The improving but still abnormal UA presents a diagnostic dilemma:

• Pyuria improvement (from >25 WBC/HPF to 5-10 WBC/HPF) suggests partial response
• Persistent LE 3+ and nitrite 2+ indicate ongoing bacterial presence
• Continued bacteriuria is concerning for inadequate source control or resistant organisms

Important Caveats About Urinalysis Interpretation

Urinalysis findings can persist even with appropriate therapy and do not always indicate treatment failure 3, 4. However, the combination of persistent LE 3+, nitrite 2+, AND bacteria after several days of susceptible therapy is concerning enough to warrant repeat culture 3, 5.

Critical Next Steps

1. Obtain Repeat Urine Culture NOW

This is non-negotiable. You need to know:

• Is the same Proteus mirabilis persisting?
• Has a second organism emerged?
• Has resistance developed during therapy?
• Is there adequate bacterial clearance?

The absence of the repeat culture you ordered is a significant gap in management 1.

2. Increase Ceftriaxone Dose

Consider increasing to ceftriaxone 2g IV daily given:

• Proteus infections can be more difficult to eradicate (urease production, biofilm formation) 6
• Higher doses are recommended for complicated UTIs 2
• Normal renal function (eGFR 104) allows for higher dosing without adjustment 7

3. Evaluate for Complicating Factors

Persistent infection despite appropriate antibiotics suggests:

• Urinary obstruction (stone, stricture)
• Abscess formation (perinephric, renal)
• Structural abnormality (requiring imaging if not already done)
• Inadequate source control
• Biofilm-associated infection 6

The alkaline urine and Proteus species raise concern for struvite stone formation, which can harbor bacteria and prevent cure 6.

4. Consider Transition Strategy

Once repeat culture results return:

• If susceptibilities unchanged and clinical improvement continues: complete 10-14 days total therapy 1, 8
• If clinically stable with improving symptoms: consider IV-to-PO conversion after 48-72 hours of clinical stability, using an oral agent with documented susceptibility 9
• Oral options if susceptible: trimethoprim-sulfamethoxazole, cefpodoxime, or ceftibuten (NOT ciprofloxacin given documented resistance) 2, 8

Common Pitfalls to Avoid

1. Don't assume persistent UA abnormalities equal treatment failure without culture confirmation 3, 4
2. Don't switch to empiric broad-spectrum therapy without culture data—you have documented susceptibilities
3. Don't use fluoroquinolones despite their convenience—your organism is resistant 10
4. Don't underdose β-lactams in complicated UTIs—use 2g daily 2
5. Don't forget to image if you haven't already—Proteus + alkaline urine = possible stones

Summary Algorithm

Immediate actions:

• Continue ceftriaxone (increase to 2g IV daily)
• Obtain repeat urine culture and susceptibilities
• Ensure adequate imaging has been performed

After culture results:

• If same organism, same susceptibilities, clinical improvement → complete 10-14 days total
• If new organism or changed susceptibilities → adjust therapy accordingly
• If persistent infection despite appropriate therapy → investigate for structural abnormality or abscess

Transition planning:

• After 48-72 hours clinical stability → consider IV-to-PO conversion to susceptible oral agent
• Total duration: 10-14 days for complicated UTI/pyelonephritis with β-lactam therapy 1, 8